Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biomea Fusion Inc (BMEA)

Biomea Fusion Inc (BMEA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 318,398
  • Shares Outstanding, K 28,998
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,324 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.94
Trade BMEA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.82
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/26/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.33
  • Number of Estimates 3
  • High Estimate -0.19
  • Low Estimate -0.41
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.00 +9.80%
on 08/19/21
14.85 -26.06%
on 09/01/21
+0.10 (+0.92%)
since 08/17/21
3-Month
10.00 +9.80%
on 08/19/21
20.88 -47.41%
on 06/18/21
-9.75 (-47.03%)
since 06/17/21

Most Recent Stories

More News
Biomea Fusion Announces FDA Clearance of Investigational New Drug Application for Irreversible Menin Inhibitor BMF-219

-- BMF-219 advances as the first clinical stage therapeutic from the company's deep pipeline of covalent irreversible small molecules

BMEA : 10.98 (-11.95%)
Biomea Fusion Reports Second Quarter 2021 Financial Results and Business Highlights

-- Continued to advance ongoing preclinical studies of BMF-219 in a number of menin-dependent liquid and solid tumors, including Diffuse Large B Cell Lymphoma ("DLBCL"), to expand potential impact of novel...

FSNN : 0.0580 (-19.44%)
BMEA : 10.98 (-11.95%)
BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer

Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically...

FSNN : 0.0580 (-19.44%)
BMEA : 10.98 (-11.95%)
EIDX : 122.21 (-4.85%)
BBIO : 52.12 (+5.59%)
IOVA : 25.47 (+8.15%)
Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights

-- Received $167 million in aggregate gross proceeds in April from initial public offering --

FSNN : 0.0580 (-19.44%)
BMEA : 10.98 (-11.95%)
Biomea Announces Closing of Initial Public Offering

Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients...

FSNN : 0.0580 (-19.44%)
JPM : 157.68 (-0.26%)
BMEA : 10.98 (-11.95%)
Biomea Announces Pricing of Initial Public Offering

Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients...

FSNN : 0.0580 (-19.44%)
JPM : 157.68 (-0.26%)
BMEA : 10.98 (-11.95%)

Business Summary

Biomea Fusion Inc. is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion Inc. is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 12.90
2nd Resistance Point 12.45
1st Resistance Point 11.71
Last Price 10.98
1st Support Level 10.52
2nd Support Level 10.07
3rd Support Level 9.33

See More

52-Week High 22.22
Fibonacci 61.8% 17.55
Fibonacci 50% 16.11
Fibonacci 38.2% 14.67
Last Price 10.98
52-Week Low 10.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar